Dong-E-E-Jiao Co., Ltd. (SHE:000423)
47.93
+0.60 (1.27%)
Oct 30, 2026, 3:04 PM CST
Dong-E-E-Jiao Revenue
Dong-E-E-Jiao had revenue of 1.79B CNY in the quarter ending September 30, 2026, with 4.10% growth. This brings the company's total for the last twelve months to 6.87B, up 8.12% year-over-year. In the year 2025, Dong-E-E-Jiao had annual revenue of 6.70B with 8.83% growth. That makes Dong-E-E-Jiao the 7,485th largest company in the world by revenue and 1,093rd in China.
Revenue (ttm)
6.87B
Revenue Growth
+8.12%
P/S Ratio
4.45
Revenue / Employee
1.58M
Employees
4,345
Market Cap
30.59B
Revenue by Geography
- East China 3.63B 54.1%
- Central China 1.02B 15.2%
- South China 617.53M 9.2%
- North China 555.84M 8.3%
- Southwest China 522.37M 7.8%
- Northwest China 249.96M 3.7%
- Northeast China 72.23M 1.1%
- Other Regions of China 39.11M 0.6%
Fiscal year ended Dec 31, 2025 See the full Dong-E-E-Jiao breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.70B | 543.77M | 8.83% |
| Dec 31, 2024 | 6.16B | 1.44B | 30.57% |
| Dec 31, 2023 | 4.72B | 673.45M | 16.66% |
| Jan 1, 2023 | 4.04B | 192.83M | 5.01% |
| Jan 1, 2022 | 3.85B | 439.55M | 12.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| China Resources Sanjiu Medical & Pharmaceutical | 31.03B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 15.87B |
| Changchun High-Tech Industry (Group) | 10.53B |
| Livzon Pharmaceutical Group | 10.22B |
| Zhejiang Huahai Pharmaceutical | 9.60B |
| Shijiazhuang Yiling Pharmaceutical | 7.93B |
| Hubei Jumpcan Pharmaceutical | 5.92B |
Dong-E-E-Jiao News
- 8 days ago - Dong-E-E-Jiao Quarterly report: Q3 2026 - Filings
- 2 months ago - Dong-E-E-Jiao Quarterly report: Q2 2026 - Filings
- 6 months ago - Dong-E-E-Jiao Quarterly report: Q1 2026 - Filings
- 7 months ago - Dong-E-E-Jiao Earnings release: Q4 2025 - Filings
- 7 months ago - Dong-E-E-Jiao Annual report: Q4 2025 - Filings